Drug · DIN 02374129
COMPLERA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 4, 2014; first marketed October 20, 2011.
- Drug Identification Number (DIN)
- 02374129
- Company (DIN owner)
- Gilead Sciences Canada IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Emtricitabine, tenofovir disoproxil and rilpivirine J05AR08
- Class
- Human
- Record last updated
- June 15, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| EMTRICITABINE | 200 MG | |
| RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE) | 25 MG | |
| TENOFOVIR DISOPROXIL FUMARATE | 300 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 3, 2014: NOC 16161Supplement to a New Drug Submission (SNDS) · The PM was updated in the following sections: Indications & Clinical Use, Contraindications, Warnings & Precautions, Adverse Reactions, Drug Interactions, Dosage & Administration, Virology and Consumer Information.
- September 23, 2011: NOC 12653New Drug Submission (NDS)